The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer

References

• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstetrics Gynaecol. 2017 May;41:3–14.
   PubMed Web of Science ®Google Scholar
• Lisio M-A, Fu L, Goyeneche A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019 Feb 22;20:4.
   Web of Science ®Google Scholar
• Klotz DM, Wimberger P. Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube? Arch Gynecol Obstet. 2017 Dec;296(6):1055–1062.
   PubMed Web of Science ®Google Scholar
• Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017;29(1):26–34.
   PubMed Web of Science ®Google Scholar
• Gee ME, Faraahi Z, McCormick A, et al. DNA damage repair in ovarian cancer: unlocking the heterogeneity. J Ovarian Res. 2018 Dec;11(1):50.
   PubMedGoogle Scholar
• Hunter MV, Moncada R, Weiss JM, et al. Spatial transcriptomics reveals the architecture of the tumor/microenvironment interface [Internet]. Cancer Biology; 2020 Nov. Available from: http://biorxiv.org/lookup/doi/10.1101/2020.11.05.368753
   Google Scholar
• Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016 Apr;13(4):255–261.
   PubMed Web of Science ®Google Scholar
• Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011 Jan 8;377(9760):127–138.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019 Mar;393(10177):1240–1253.
   PubMed Web of Science ®Google Scholar
• Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131(5):909–927.
   PubMed Web of Science ®Google Scholar
• Weiland F, Martin K, Oehler MK, et al. Deciphering the molecular nature of ovarian cancer biomarker CA125. IJMS. 2012 Aug 22;13(8):10568–10582.
   Google Scholar
• Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016 Nov;143(2):270–275.
   PubMed Web of Science ®Google Scholar
• Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012 May;22(Suppl 1):S24–26.
   PubMedGoogle Scholar
• Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016 Mar 5;387(10022):945–956.
   PubMed Web of Science ®Google Scholar
• Elias KM, Guo J, Bast RC. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018 Dec;32(6):903–914.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008 May;18(3):414–420.
   PubMed Web of Science ®Google Scholar
• Glubb DM, Thompson DJ, Aben KK, et al. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. Cancer Epidemiol Biomarkers Prev.2020;Nov:Vol. 3; cebp.0739.2020.
   Google Scholar
• Ratner E, Lu L, Boeke M, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010 Aug 15;70(16):6509–6515.
   PubMed Web of Science ®Google Scholar
• Asante D-B, Calapre L, Ziman M, et al. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time? Cancer Lett. 2020;468:59–71.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Comino-Méndez I, De Bruijn I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res. 2017 Nov 1;23(21):6708–6720.
   PubMed Web of Science ®Google Scholar
• Clements J, Hooper J, Dong Y, et al. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential funtions. Biol Chem. 382(1)Internet]. 2001 Jan 6 [2021 Feb 24]; Available from: https://www.degruyter.com/view/j/bchm.2001.382.issue-1/bc.2001.002/bc.2001.002.xml
   PubMed Web of Science ®Google Scholar
• Loessner D, Goettig P, Preis S, et al. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Expert Opin Ther Targets. 2018 Sep 2;22(9):745–763.
   PubMed Web of Science ®Google Scholar
• Filippou PS, Karagiannis GS, Musrap N, et al. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. Crit Rev Clin Lab Sci. 2016 Jul 3;53(4):277–291.
   PubMed Web of Science ®Google Scholar
• Yu Y, Prassas I, Diamandis EP. Putative kallikrein substrates and their (patho)biological functions. Biol Chem. 2014 Sep 1;395(9):931–943.
   PubMed Web of Science ®Google Scholar
• Bronger H, Magdolen V, Goettig P, et al. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. Cancer Metastasis Rev. 2019 Sep;38(3):417–430.
   PubMed Web of Science ®Google Scholar
• Stefanini ACB, Da Cunha BR, Henrique T, et al. Involvement of kallikrein-related peptidases in normal and pathologic processes. Dis Markers. 2015;2015:1–17.
   Web of Science ®Google Scholar
• Prassas I, Eissa A, Poda G, et al. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015 Mar;14(3):183–202.
   PubMed Web of Science ®Google Scholar
• Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007 Aug 1;53(8):1423–1432.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Magdolen V, Yang F, et al. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol Oncol. 2013 Dec 1;47(4):319–329.
   PubMed Web of Science ®Google Scholar
• Obiezu CV, Scorilas A, Katsaros D, et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res. 2001 Aug;7(8):2380–2386.
   PubMed Web of Science ®Google Scholar
• Gong W, Liu Y, Seidl C, et al. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients. Ulrich H, editor. PLoS ONE. 2019;Feb 27 14(2):e0212968.
   PubMed Web of Science ®Google Scholar
• Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res. 2001 Aug;7(8):2363–2371.
   PubMed Web of Science ®Google Scholar
• Xi Z, Kærn J, Davidson B, et al. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol. 2004 Jul;94(1):80–85.
   PubMed Web of Science ®Google Scholar
• Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 2004 May;122(5):1235–1244.
   PubMed Web of Science ®Google Scholar
• Kim H, Scorilas A, Katsaros D, et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001 Mar 2;84(5):643–650.
   PubMed Web of Science ®Google Scholar
• Gong W, Liu Y, Seidl C, et al. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer. BMC Cancer. 2019 Dec;19(1):696.
   PubMedGoogle Scholar
• Dong Y, Kaushal A, Brattsand M, et al. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res. 2003 May;9(5):1710–1720.
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Borgoño CA, Scorilas A, et al. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumor Biol. 2003;24(6):299–309.
   PubMedGoogle Scholar
• Dorn J, Bronger H, Kates R, et al. OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. Oncol Lett. 2015 Jan;9(1):418–424.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Polymeris M-E, Grass L, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003 Jul 15;63(14):3958–3965.
   PubMed Web of Science ®Google Scholar
• Bandiera E, Zanotti L, Bignotti E, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer. 2009 Jul;19(6):1015–1021.
   PubMed Web of Science ®Google Scholar
• Dorn J, Magdolen V, Gkazepis A, et al. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival. Ann Oncol. 2011 Aug;22(8):1783–1790.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Li L, Zheng Y, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 2008 Oct;99(7):1103–1113.
   PubMed Web of Science ®Google Scholar
• Kuk C, Kulasingam V, Gunawardana CG, et al. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics. 2009 Apr;8(4):661–669.
   PubMed Web of Science ®Google Scholar
• Ni X, Zhang W, Huang K-C, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer. 2004 Aug 16;91(4):725–731.
   PubMed Web of Science ®Google Scholar
• Seiz L, Dorn J, Kotzsch M, et al. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem. 2012 May 1;393(5):391–401.
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Psyrri A, Scorilas A, et al. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemost. 2009 Mar;101(3):541–546.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Dorn J, Napieralski R, et al. Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Biol Chem. 2016 Dec 1;397(12):1265–1276.
   PubMed Web of Science ®Google Scholar
• Hu C-J, Zhang F, Chen Y-J, et al. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):520–523.
   PubMedGoogle Scholar
• Tamir A, Jag U, Sarojini S, et al. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014 Dec;7(1):109.
   PubMedGoogle Scholar
• White NMA, Mathews M, Yousef GM, et al. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer. 2009 Oct;101(7):1107–1113.
   PubMed Web of Science ®Google Scholar
• Yang F, Hu Z-D, Chen Y, et al. Diagnostic value of KLK6 as an ovarian cancer biomarker: a meta-analysis. Biomed Rep. 2016 Jun;4(6):681–686.
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. JCO. 2003 Mar 15;21(6):1035–1043.
   PubMed Web of Science ®Google Scholar
• Koh SCL, Huak CY, Lutan D, et al. Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. J Gynecol Oncol. 2012 Jul;23(3):175–181.
   PubMed Web of Science ®Google Scholar
• Bandiera E, Zanotti L, Fabricio ASC, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 51(9)Internet]. 2013 Jan 1 [2021 Feb 24]; Available from: https://www.degruyter.com/doi/10.1515/cclm-2013-0151
   PubMed Web of Science ®Google Scholar
• Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Nov;99(2):267–277.
   PubMed Web of Science ®Google Scholar
• Mah ES, Sallam MM, Shaban EAK, et al. Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. Int J Gynecol Cancer. 2011 Apr;21(4):625–632.
   PubMed Web of Science ®Google Scholar
• Leung F, Bernardini MQ, Brown MD, et al. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333–1340.
   PubMed Web of Science ®Google Scholar
• Chen E, Zhu H, Yang Y, et al. Analysis of expression and prognosis of KLK7 in ovarian cancer. Open Med (Wars). 2020;15(1):932–939.
   PubMedGoogle Scholar
• Shan SJC, Scorilas A, Katsaros D, et al. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem. 2006 Oct 1;52(10):1879–1886.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Kountourakis P, Scorilas A, et al. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann Oncol. 2008 Jul;19(7):1271–1277.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulou LG, Yousef GM, Scorilas A, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003 Mar;36(2):135–143.
   PubMed Web of Science ®Google Scholar
• Gong W, Liu Y, Diamandis EP, et al. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer. J Ovarian Res. 2020 Oct 21;13(1):125.
   PubMed Web of Science ®Google Scholar
• Dorn J, Gkazepis A, Kotzsch M, et al. Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol Chem. 2014 Jan;395(1):95–107.
   PubMed Web of Science ®Google Scholar
• Magklara A, Scorilas A, Katsaros D, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001 Apr;7(4):806–811.
   PubMed Web of Science ®Google Scholar
• Borgoño CA, Kishi T, Scorilas A, et al. Human kallikrein 8 protein Is a favorable prognostic marker in ovarian cancer. Clin Cancer Res. 2006 Mar 1;12(5):1487–1493.
   PubMed Web of Science ®Google Scholar
• Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003 Jun 1;63(11):2771–2774.
   PubMed Web of Science ®Google Scholar
• Shih I-M, Salani R, Fiegl M, et al. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol. 2007 May;105(2):501–507.
   PubMed Web of Science ®Google Scholar
• Shigemasa K, Tian X, Gu L, et al. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep. 2004 Jun 1 2021 Jan 10. Available from: http://www.spandidos-publications.com/10.3892/or.11.6.1153
   Web of Science ®Google Scholar
• Gilks CB, Vanderhyden BC, Zhu S, et al. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 2005 Mar;96(3):684–694.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015 Nov;5(11):1137–1154.
   PubMed Web of Science ®Google Scholar
• Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003 Jul;90(1):44–50.
   PubMed Web of Science ®Google Scholar
• Luo L-Y, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003 Feb 15;63(4):807–811.
   PubMed Web of Science ®Google Scholar
• Dorn J, Harbeck N, Kates R, et al. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol. 2011 Apr;22(4):877–883.
   PubMed Web of Science ®Google Scholar
• Geng X, Liu Y, Dreyer T, et al. Elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a better prognosis in advanced high-grade serous ovarian cancer patients. Am J Cancer Res. 2018;8(9):1856–1864.
   PubMed Web of Science ®Google Scholar
• Planque C, Aïnciburu M, Heuzé-Vourc’h N, et al. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem. 2006 Jun;387(6):783–788.
   PubMed Web of Science ®Google Scholar
• Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev. 2010 Aug 1;31(4):407–446.
   PubMed Web of Science ®Google Scholar
• Meinhold-Heerlein I, Bauerschlag D, Zhou Y, et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res. 2007 Jan 15;13(2):458–466.
   PubMed Web of Science ®Google Scholar
• Geng X, Liu Y, Diersch S, et al. Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer. Ulrich H, editor. PLoS ONE. 2017;Nov 2 12(11):e0186847.
   PubMed Web of Science ®Google Scholar
• Shigemasa K, Gu L, Tanimoto H, et al. Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res. 2004 Apr 15;10(8):2766–2770.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Katsaros D, Shan SJC, et al. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res. 2007 Dec 1;13(23):6984–6992.
   PubMed Web of Science ®Google Scholar
• McIntosh MW, Liu Y, Drescher C, et al. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res. 2007 Aug 1;13(15):4422–4428.
   PubMed Web of Science ®Google Scholar